Dr. Ruiz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-732-5500
Education & Training
- Montefiore Medical Center/Albert Einstein College of MedicineResidency, Dermatology, 2011 - 2014
- NYU Grossman School of MedicineInternship, Internal Medicine, 2010 - 2011
- New York University School of MedicineClass of 2010
Certifications & Licensure
- MA State Medical License 2014 - 2025
- NY State Medical License 2011 - 2015
- American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- Definitive Radiation Therapy is a Viable Treatment for Locally Advanced Basal Cell Carcinoma Otherwise Requiring Radical or Disfiguring Resection.William Su, Emily J Anstadt, Neha Gupta, Morgan Groover, Vernon Forrester
International Journal of Radiation Oncology, Biology, Physics. 2025-03-01 - Mohs Surgery vs Wide Local Excision in Primary High-Stage Cutaneous Squamous Cell Carcinoma.David M Wang, Michelangelo Vestita, Fadi G Murad, Frederick C Morgan, Rachael Rowley
JAMA Dermatology. 2025-02-19 - Self supervised artificial intelligence predicts poor outcome from primary cutaneous squamous cell carcinoma at diagnosis.Nicolas Coudray, Michelle C Juarez, Maressa C Criscito, Adalberto Claudio Quiros, Reason Wilken
NPJ Digital Medicine. 2025-02-15
Press Mentions
- Dr. Ruiz Presents 10 Clinical Highlights in Cutaneous Oncology at Maui DermJanuary 31st, 2025
- FDA Approves Cosibelimab-Ipdl for Advanced Cutaneous Squamous Cell CarcinomaDecember 17th, 2024
- Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b TumorsOctober 20th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: